We have generated a monospecific antibody to a synthetic peptide encoded by an RNA complementary to the mRNA for angiotensin II (AII) and determined whether this antibody recognizes the AII receptor. We demonstrate that the antibody competes specifically with "25I-labeled All for the same binding site on rat adrenal membranes. Furthermore, we show that this antibody inhibits the secretion of aldosterone from cultured rat adrenal cells, suggesting that the antibody recognizes the biologically relevant AII receptor.
Finally, we demonstrate that antibody to the complementary peptide can be used to immunoaffinity-purify a protein of Mr 66,000 that specifically binds radiolabeled All.
Angiotensin II (All), an octapeptide hormone, is the biologically active component of the renin-angiotensin system (1, 2) . All mediates vasoconstriction (3) and aldosterone secretion (4) through specific interactions with All receptors present on vascular smooth muscle (3) and adrenal glands (4) , respectively. To understand how the binding of All with its specific receptor mediates a precise biochemical effect, the All receptor must be purified and characterized. Recently, several research groups have identified an apparent All binding protein of Mr 66,000 by means of photoaffinity labeling (5) (6) (7) (8) (9) , crosslinking (10, 11) , and affinity chromatography (12) . While these techniques are useful tools for the characterization of the All receptor, they have not resulted in its purification to homogeneity.
Recently, it was hypothesized that there is a molecular recognition code in which peptide ligands and their receptor binding sites can be encoded by complementary nucleotide sequences (13) . In support of this hypothesis, several laboratories have demonstrated that peptides encoded by complementary strands of nucleic acids (designated "complementary peptides") have the ability to bind one another (13) (14) (15) using the same reading frame. For example, it was shown that complementary peptides to corticotropin, yendorphin, and luteinizing hormone-releasing hormone would bind to their respective hormone with high affinity and specificity, suggesting that the complementary peptides resembled receptor binding sites (13, (16) (17) (18) (19) (20) . Furthermore, it was demonstrated that antibodies directed against a peptide complementary to a particular hormone would also bind to that hormone's receptor binding site (13, (16) (17) (18) (19) (20) . In fact, antibodies directed against peptides complementary to corticotropin, y-endorphin, and luteinizing hormone-releasing hormone have been used to immunoafflinity-purify these specific hormone receptors (13, (16) (17) (18) (19) (20) .
In this report, we have investigated the usefulness of the molecular recognition hypothesis in the purification of the All receptor. Specifically, we have determined whether a peptide, IIA, specified by RNA complementary to the mRNA of All would bind All and, if so, whether antibodies to such a peptide would sufficiently resemble an All binding site that they would crossreact with the All receptor. few minor modifications. Briefly, fresh rat adrenal glands were homogenized in ice-cold 50 mM Tris HCI, pH 7.5/5 mM EDTA/0.1 mM phenyl methylsulfonyl fluoride with a loose-fitting Dounce homogenizer. The homogenate was then filtered through nylon gauze and centrifuged at 600 x g for 10 min. The supernatant was centrifuged at 30,000 x g for 30 min, and the pellet (adrenal particles) was resuspended in the appropriate buffer. In some experiments, the adrenal particles were purified further with the use of discontinuous sucrose gradients (22) .
MATERIALS AND METHODS

Materials
All Receptor Binding Assays. 1251I-AII (0.01 nM) was incubated for 60 min at 22°C in 0.01-0.2 ml of assay buffer (50 mM Tris-HCl, pH 7.5/120 mM NaCl/5 mM EDTA/0.2% bovine serum albumin) with 100-200 ,ug of adrenal particles and various concentrations of unlabeled All, [Sar',Ile8]AII, control peptide, anti-IIA IgG, or control IgG. The reactions were stopped by filtration on GF/B glass filters, followed by four rapid washings with 5 ml of ice-cold incubation buffer. Nonspecific binding was measured in the presence of an excess of unlabeled All (10 AM) and always represented <10% of total bound radioactivity.
All Receptor Affinity Purification. Affinity-purified anti-IIA IgG was coupled to agarose beads, Reacti-Gel 6X, as described by the manufacturer. Rat adrenal particles (5 mg) were resuspended in PBS and solubilized with CHAPS as described (17) . The solubilized adrenal particles were centrifuged at 700 x g for 10 min, and the supernatant was diluted 1:6 with PBS. The diluted supernatant was then chromatographed on the anti-IIA IgG affinity column. Material that bound to the column was eluted with 3 M MgCl2, collected, and dialyzed against H20 overnight. The material was then dehydrated by extraction with polyethylene glycol and subsequently analyzed by polyacrylamide gel electrophoresis. In some experiments, adrenal particles were resuspended in PBS, sonicated for 1 min, and then subjected to affinity chromatography.
Specific All Binding to Immunoaffinity-Purified Protein. Protein that bound to the anti-IIA IgG affinity column (1-50 ,ug) was incubated with 125I-AII (0.2 nM) in the presence or absence of nonlabeled All (10 ,uM) at 4°C for 1 hr in 500 Al of PBS (pH 7.4). These samples were then crosslinked with 3.0 mM disuccinimidyl suberate in dimethyl sulfoxide for 15 min at 25°C. Finally, the samples were dialyzed for 18 hr against PBS to remove free 125I-AII, hydroextracted with polyethylene glycol, and subjected to polyacrylamide gel electrophoresis.
Polyacrylamide Gel Electrophoresis. Gel electrophoresis was performed on homogeneous slab gels (7.5% acrylamide) (25) . After electrophoresis, gels were stained for protein by a silver-staining method as described (26) . After staining, some gels were dried and subjected to autoradiography at -90°C. The autoradiograph was scanned with a densitomeric scanner (Hoefer, San Francisco).
RESULTS
We initially investigated whether a complementary All peptide would interact with All in a specific manner. Therefore, we synthesized a complementary All peptide based on the rat angiotensinogen cDNA nucleotide sequence obtained from Ohkubo et al. (21) . The amino acid and mRNA sequences for rat All are shown in Fig. 1 . Also shown in Fig.   1 (Fig. 2) and did not occur if the cells were preincubated with IIA and subsequently washed (data not shown), indicating that IIA is not binding to the All receptor. Furthermore, the inhibition of 1251I-AII binding appeared to be specific because control peptides did not significantly inhibit the binding of radiolabeled All, even at concentrations of 0.1 mM (Fig. 2) . These experiments suggest that the complementary peptide IIA Biochemistry: Elton et al. Proc . NatL. Acad. Sci. USA 85 (1988) interacts specifically with 125I-AII and, thus, interferes with its ability to bind to adrenal All receptors.
To determine if the interaction between IIA and All was due to the complementary peptide having a shape or conformation resembling the All receptor, an antibody was prepared against IIA and evaluated for its ability to recognize the All receptor binding site. Fig. 2 shows that affinitypurified anti-IIA IgG inhibits the binding of radiolabeled All to All receptors. Additionally, Table 1 shows that anti-IIA IgG inhibits the secretion of aldosterone from freshly dispersed rat adrenal glomerulosa cells. In contrast, control IgG (preimmune serum) did not block 1251I-AII binding or inhibit the spontaneous or All-mediated release of aldosterone (data not shown). Taken together, these results suggest that anti-IIA IgG specifically recognizes All binding sites.
To investigate whether antibodies against IIA could be used to affinity-purify the All binding protein, anti-IIA IgG was coupled to Reacti-Gel agarose beads. Rat adrenal particles were solubilized with CHAPS and chromatographed on the immunoaffinity column. The material that bound to the column was eluted and subjected to NaDodSO4/polyacrylamide gel electrophoresis. The electrophoretic results presented in Fig. 3 show that the immunoaffinity-purified material consists of a single protein species. Purified protein that was treated with 2-mercaptoethanol (5%) migrated as a Mr 66,000 ± 2,000 polypeptide during electrophoresis (Fig.  3, lane 2) . Interestingly, in the absence of a reducing agent, the purified protein migrated faster, with a Mr 58,000 + 2,000 (Fig. 3, lane 1) . These data suggest that the immunoaffinity-purified protein contains intramolecular disulfide bridges.
To demonstrate that this protein actually contains the All binding site, it was incubated with 251I-AII in the absence or presence of unlabeled All and crosslinked with disuccinimidyl suberate. The crosslinked material was electrophoresed, silver-stained, and finally subjected to autoradiography. The silver-stained gel displayed in Fig. 4A again shows that the immunoaffinity-purified material consists of a single protein species (Mr 66,000 ± 2,000), even with the lanes being overloaded (lanes 1 and 2) . Fig. 4B shows the autoradiograph of this gel. It is apparent that the immunoaffinity-purified protein could bind 1251I-AII (Fig. 4B, lane 1) . Furthermore, these results strongly suggest that this binding is specific, since the amount of radiolabeled All binding was reduced when the protein was incubated in the presence of unlabeled All (Fig. 4B, lane 2) . In fact, the densitometric evaluation of the data in Fig. 4B shows that "25I-AII binding was reduced -80% in the presence of unlabeled All (Fig. 4C) . binding sites can be encoded by complementary nucleotide sequences (13) . To test this hypothesis, we have utilized the nucleotide sequence of the rat angiotensinogen cDNA (21) to synthesize a peptide complementary to All.
In (28, 29) , the hepatic glucagon receptor (30), the opiate receptor purified from bovine striatum (31), the receptors for interleukin 2 (32) and interleukin 3 (33), the luteinizing hormone/human chorionic gonadotropin receptor (34) , and the putative All binding protein (12) display a similar mobility shift after reduction. Moxham and Malbon (28) have shown that the integrity of one or more intramolecular disulfide bridges is essential for ligand binding, and chemical cleavage of these bonds destabilizes the ability of a /3l-adrenergic receptor to bind radioligands. Creighton (35) has suggested that agonist binding may promote disulfide exchange reactions and/or cleavage of intramolecular disulfide bridges and transform the receptor into a structurally altered state capable of activating guanine nucleotide proteins. Recently, it has been shown that All receptors interact with these regulatory proteins (36) (37) (38) (39) .
In this study, other peptides were complementary at the amino acid level rather than nucleotide level, with sequence homology between All and these antagonists apparently resulting from one portion of All being complementary to another. Such homology would account for the binding of these peptides to the All receptor rather than All itself. Also, the complementary peptide approach was recently used to purify the cellular receptor for fibronectin (40) .
